Nepafenac
Pronunciation: ne-pa-FEN-ak
Class: NSAID
Trade Names
Nevanac
- Ophthalmic Suspension 0.1%
Pharmacology
Decreases inflammation by blocking prostaglandin H synthase, an enzyme required for prostaglandin production.
Indications and Usage
Treatment of pain and inflammation associated with cataract surgery.
Contraindications
Standard considerations.
Dosage and Administration
Adults and Children 10 yr of age and olderOphthalmic 1 drop to affected eye 3 times daily beginning 1 day prior to cataract surgery and continued on the day of surgery and through the first 2 wk of the postoperative period.
General Advice
- Shake well before use.
- May be used in conjunction with other topical ophthalmic medications (eg, beta-blockers).
Storage/Stability
Store at 36° to 77°F.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Cardiovascular
Hypertension (1% to 4%).
CNS
Headache (1% to 4%).
EENT
Capsular opacity, decreased visual acuity, foreign body sensation, increased IOP, sticky sensation (5% to 10%); conjunctival edema, corneal edema, dry eye, lid-margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, vitreous detachment (1% to 5%).
GI
Nausea/vomiting (1% to 4%).
Respiratory
Sinusitis (1% to 4%).
Precautions
Pregnancy
Category C .
Lactation
Undetermined.
Children
Safety and efficacy not established in children younger than 10 yr of age.
Special Risk Patients
Use with caution in patients with complicated ocular surgery, corneal denervation, corneal surface disease (eg, dry eye syndrome), rheumatoid arthritis, known bleeding tendencies, or repeat ocular surgeries within a short period of time.
Bleeding
There is a potential for increased bleeding time caused by interference with thrombocyte aggregation.
Corneal events
Use of product more than 1 day prior to surgery or beyond 14 days post surgery may increase the risk for occurrence and severity of corneal adverse reactions.
Cross-sensitivity
Because of potential cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, use caution when treating patients previously exhibiting sensitivity to these agents.
Healing
Healing may be slowed or delayed.
Keratitis
Continued use may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, which may be sight threatening.
Overdosage
Symptoms
None specified.
Patient Information
- Advise patients not to administer while wearing contact lenses.
Copyright © 2009 Wolters Kluwer Health.
More Nepafenac resources
- Ilevro Prescribing Information (FDA)
- Ilevro MedFacts Consumer Leaflet (Wolters Kluwer)
- Nevanac Prescribing Information (FDA)
- Nevanac Advanced Consumer (Micromedex) - Includes Dosage Information
- Nevanac Consumer Overview
- Nevanac Monograph (AHFS DI)


